Celldex Therapeutics (CLDX) SVP and CFO Bates Buys 93,000 Shares
Martin Bates, CFO of Celldex, acquired 93,000 shares, signaling confidence in the company's future.
Reviewed by automated data checks against the source filing. How we make and check alerts
Martin Samuel Bates, SVP AND CFO at Celldex Therapeutics, Inc. ($CLDX), bought 93,000 shares on June 25, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CLDX is up 12.6% after 1 week, up 4.6% after 1 month and down 19.2% to date (from the $34.09 close on Jun 25, 2026).
CLDX
Celldex Therapeutics, Inc.
Key Points
- Martin Bates, the CFO of Celldex Therapeutics, purchased 93,000 shares on June 25, 2026.
- Celldex Therapeutics has a market cap of $2.77 billion, with shares trading at $35.26 on Tuesday.
- Analysts from firms like HC Wainwright & Co. and UBS maintain a 'buy' rating on Celldex, with price targets up to $68.
Get $CLDX trade alerts by text
We text you when insiders, Congress or big funds trade $CLDX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Celldex Therapeutics, Inc. alert may contain errors. Disclosures
Celldex Therapeutics, Inc.'s CFO, Martin Samuel Bates, made a substantial purchase of 93,000 shares on June 25, 2026. This insider activity reflects a significant show of confidence from the company's senior financial officer.
Insider Buying and Selling at Celldex Therapeutics, Inc.
On June 25, 2026, several insiders at Celldex Therapeutics, including Martin Samuel Bates, the Senior Vice President and CFO, bought shares in the company. Bates acquired 93,000 shares, while other executives such as Ronald Pepin, Denice Torres, and Neil Garry Arthur also made purchases. These transactions were not part of any pre-arranged trading plans.
Celldex Therapeutics, Inc. Stock Down 2.1%
Shares of NasdaqCM:CLDX traded at $35.26 on Tuesday. Celldex Therapeutics has a market cap of approximately $2.77 billion. The stock has a 52-week range between $19.52 and $35.79, with a 50-day moving average of $32.10 and a 200-day moving average of $28.27. The company, which operates in the biotechnology sector, shows a current ratio of 8.92 and a quick ratio of 8.78, indicating strong liquidity.
Analysts Set New Price Targets
Analysts are optimistic about Celldex's future. On June 15, 2026, HC Wainwright & Co. reiterated a 'buy' rating with a target price of $42. UBS maintained its 'buy' rating with a $45 target on June 10. Wells Fargo and Barclays also maintain 'buy' ratings, with targets of $54 and $48, respectively. The analyst consensus is a 'strong buy' with a mean target price of $57.53, reflecting positive sentiment about the company's potential.
About Celldex Therapeutics
Celldex Therapeutics, Inc. is a biopharmaceutical company based in Hampton, New Jersey. It focuses on developing therapeutic antibodies for severe inflammatory, allergic, autoimmune, and other diseases. The company's pipeline includes monoclonal and bispecific antibodies targeting mast cell mediated diseases. Led by CEO Anthony S. Marucci, Celldex employs 198 people and continues to advance its clinical programs.
Bottom Line
The recent insider buying by Celldex Therapeutics' CFO, Martin Bates, is a notable event that investors often watch for signs of executive confidence. While 13F filings and insider transactions provide a historical snapshot, they do not necessarily indicate current positions or future performance. Analyst ratings remain positive, suggesting a strong outlook for the company.
Related Filing Alerts
Source: Martin Samuel Bates's Form 4 filing on $CLDX (Jun 25, 2026). Find the original filing: CLDX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts